Identification of potential multitarget antimalarial drugs [4]

JAMA

Volumn 294, Issue 12, 2005, Pages 1490-1491

  Jenwitheesuk, Ekachai ^a   Samudrala, Ram ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 CYS PERIDOXIN; 1 [N,O BIS(5 ISOQUINOLINESULFONYL) N METHYLTYROSYL] 4 PHENYLPIPERAZINE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 21 [4 [2,6 BIS(1 PYRROLIDINYL) 4 PYRIMIDINYL] 1 PIPERAZINYL]PREGNA 1,4,9(11) TRIENE 3,20 DIONE; 4,6 DIAMINO 1,2 DIHYDRO 2,2 DIMETHYL 1 [3 (2,4,5 TRICHLOROPHENOXY)PROPOXY] 1,3,5 TRIAZINE; ADENYLOSUCCINATE SYNTHASE; ANTIMALARIAL AGENT; BISINDOLYLMALEIMIDE; COELENTERAZINE; CYCLOPHILIN; DAUNORUBICIN; DIHYDROFOLATE REDUCTASE; EH 58; FRUCTOSE BISPHOSPHATE ALDOLASE; GLUTATHIONE REDUCTASE; GLUTATHIONE TRANSFERASE; GW 8510; IMATINIB; LACTATE DEHYDROGENASE; METHYLGENE; NITROBLUE TETRAZOLIUM; PHTHALYLSULFATHIAZOLE; PLASMEPSIN II; PROTOPORPHYRIN; PYRIMETHAMINE; REMISZEWSKI; SULFAPHENAZOLE; TELOMERASE INHIBITOR; TMPYP 4; UNCLASSIFIED DRUG; UNINDEXED DRUG; PROTOZOAL PROTEIN;

CALCULATION; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG PROTEIN BINDING; DRUG RESISTANCE; LETTER; MALARIA; NONHUMAN; PATIENT COMPLIANCE; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; TREATMENT FAILURE; TREATMENT INDICATION; ANIMAL; DRUG DESIGN; DRUG EFFECT; METABOLISM; PROTEIN BINDING;

ANIMALS; ANTIMALARIALS; DRUG DESIGN; PLASMODIUM FALCIPARUM; PROTEIN BINDING; PROTOZOAN PROTEINS;

EID: 25144456051     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.294.12.1490     Document Type: Letter

References (10)

1. Baird JK. Effectiveness of antimalarial drugs. N Engl J Med. 2005;352:1565-1577.
2. Fungladda W, Honrado ER, Thimasarn K, et al. Compliance with artesunate and quininete + tracycline treatment of uncomplicated falciparum malaria in Thailand. Bull World Health Organ. 1998;76(suppl 1):59-66.
3. Csermely P, Agoston V, Pongor S. The efficiency of multi-target drugs: the network approach might help drug design. Trends Pharmacol Sci. 2005;26:178-182.
4. Ravi Chandra B, Gowthaman R, Raj Akhouri R, Gupta D, Sharma A. Distribution of proline-rich (PxxP) motifs in distinct proteomes: functional and therapeutic implications for malaria and tuberculosis. Protein Eng Des Sel. 2004;17:175-182.
5. Jenwitheesuk E, Samudrala R. Prediction of HIV-1 protease inhibitor resistance using a protein-inhibitor flexible docking approach. Antivir Ther. 2005;10:157-166.
6. ChemBank. Ligand Information Subset. Available at: http://ligand.info/ ligand_info_subset_1.sdf.zip. Accessed May 1, 2005.
7. Yuvaniyama J, Chitnumsub P, Kamchonwongpaisan S, et al. Insights into antifolate resistance from malarial DHFR-TS structures. Nat Struct Biol. 2003;10:357-365.
8. Asojo OA, Gulnik SV, Afonina E, et al. Novel uncomplexed and complexed structures of plasmepsin II, an aspartic protease from Plasmodium falciparum. J Mol Biol. 2003;327:173-181.
9. Nussenzweig RS, Long CA. Malaria vaccines: multiple targets. Science. 1994; 265:1381-1383.
10. Heppner DG Jr, Kester K, Ockenhouse CF, et al. Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research. Vaccine. 2005;23:2243-2250.